Interpretation of gene associations with risk of acute respiratory distress syndrome: P values, Bayes factors, positive predictive values, and need for replication by Sebastian Rimpau & Ari R. Joffe
Rimpau and Joffe Critical Care  (2016) 20:402 
DOI 10.1186/s13054-016-1550-8EDITORIAL Open AccessInterpretation of gene associations with risk
of acute respiratory distress syndrome: P
values, Bayes factors, positive predictive
values, and need for replication
Sebastian Rimpau and Ari R. Joffe*See related research by Perez-Marques et al., https://ccforum.biomedcentral.com/articles/10.1186/s13054-016-1454-7
This comment refers to the article available at: http://dx.doi.org/10.1186/s13054-016-1454-7.Keywords: Acute respiratory distress syndrome, Bayes factor, Gene association, P valuesSingle nucleotide polymorphisms (SNPs) in certain genes
play a role in the observed variability in development and
severity of acute respiratory distress syndrome (ARDS).
Identified SNPs can direct future studies aiming to target
diagnostic, preventive, and therapeutic interventions for
the complex pathophysiology of ARDS [1]. For example,
CFTR is involved in fluid absorption from alveoli and in
negatively modulating the inflammatory response [2, 3],
and Perez-Marques et al. report that SNPs in DNA for
proteins involved in splicing in the exon 9 region of CFTR
mRNA were independently associated with risk for ARDS
[2]. The same group have identified other statistically sig-
nificant candidate gene associations with the risk for
pediatric ARDS (Table 1) [2–7]. In adults, other candidate
gene associations with risk for development of and out-
come from ARDS have been suggested [1, 8]. How should
these gene-association hypotheses be interpreted?
Theoretical considerations: when is a
gene-association hypothesis supported?
The P value is the probability, assuming that the null hy-
pothesis (i.e., no difference between groups) is in fact
true and that all model assumptions (i.e., no selection,
attrition, analysis, or reporting bias—only chance is op-
erating) are satisfied, of obtaining a result equal to or
more extreme than what was actually observed [9, 10].
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The fallacy is to think that the P value refers to a hy-
pothesis probability, involving inductive reasoning back
from evidence (observations) to underlying truth [9–11].
This leads to misinterpretations of the P value (Table 2).
To make the inductive inference about hypothesis prob-
ability requires Bayesian methods.
Bayesian methods are conceptually simple: (Prior-odds
of null hypothesis)(Bayes factor) = (Posterior-odds of null
hypothesis) [9]. The prior-odds are based on evidence
external to the study concerning the plausibility of the
null hypothesis; in a field of study, this is the ratio of the
number of “true relationships” to “no relationships”
among those tested in the field [12]. The Bayes factor
(BF) measures the relative support, from the observed
evidence, for two hypotheses: (Probability of the data
given the null hypothesis)/(Probability of the data given
the alternative hypothesis). The BF modifies the prior
probability to give the posterior probability of the null
hypothesis (or, if one reverses the numerator and de-
nominator, the post-study probability that there is a true
association: positive predictive value (PPV)). One can
calculate, from the same numbers used to calculate the
P value, the minimum BF: the strongest evidence against
the null hypothesis, using the best supported hypothesis
(the observed association) as the alternative-hypothesis
[11]. One can also calculate the PPV of a statistically signifi-
cant finding using the prior probability of an association,
the BF based on power and alpha [BF = αβ/(1 − α)(1 − β)],
in addition to bias (affecting the accuracy of the alpha andle is distributed under the terms of the Creative Commons Attribution 4.0
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Table 1 Studies to identify risk, understand pathophysiology, and provide insight into newer individualized therapies for severity of CAP-induced ARDS in children
Study (year) Patient group (n) Time frame (years) Gene variants examined OR (unadjusted) OR (adjusted) Comment





IL-1ra: absent A1 allele MV 8.6% vs no-MV
2.6% (P = 0.003)
OR 2.65, P = 0.046 To predict MV (n = 96). Not statistically
significant if African Americans and
Caucasians analyzed separately
ARDS 9.1% vs no-ARDS
2.9%, P = 0.023
OR 3.10, P = 0.052 To predict ARDS (n = 49)
[5] (2010) African American (443) Not stated 4 MYLK SNPs P = 0.39 to 1.0 - To predict MV (n = 41) and ARDS (n = 28)
Caucasian (253) Not stated 5 MYLK SNPs P = 0.26 to 1.0 - To predict MV (n = 33) and ARDS (n = 19)








OR 2.27, P = 0.040
OR 3.00, P = 0.012
To predict MV (n = 37)
Not statistically significant if adjust for
bacterial culture positive
rs7316 P = 0.06 OR 2.95, P = 0.031 To predict ARDS (n = 26)
[3] (2012) African American (474) Not stated; 3
centers
CFTR 2 low risk vs
1 or 2 high risk
[(TG)≥12T≤5] alleles
P = 0.0013 OR 3.19, P = 0.0007 To predict MV (n = 43)
P = 0.0061 OR 3.36, P = 0.0032 To predict ARDS (n = 29). Nasal swab
was done in 113 and positive for a virus
in 43 (38%)
Caucasian (304) Not stated; 3
centers
As above P = 0.21 Not statistically
significant
To predict MV (n = 42)
P = 0.84 Not statistically
significant
To predict ARDS (n = 32). Nasal swab was
done in 89 and positive for a virus in
22 (25%)
[7] (2014) African American (443) Not stated; 3
centers
Caspase-12 long allele P = 0.83 and 0.48 - For MV (n = 41), ARDS (n = 28). Also reported
for: mortality (n = 5), severe sepsis (n = 17),
vasopressor use (n = 15), renal dysfunction
(n = 11), hematologic dysfunction (n = 9)
[2] (2016) African American (474) Not stated; 3
centers
Splicing factors of
CFTR mRNA (7 genes,
66 SNPs)
19 SNPs in 6 genes
with P < 0.20
3 SNPs in CELF-2 (OR
2.95, 4.28, and 2.66 with
P = 0.032, 0.004, and 0.044).
2 SNPs in TIA-1 (OR 3.70,
5.42 with P = 0.005, 0.018)
ARDS (n = 29). Also (TG)≥12T≤5 allele
(OR 3.01, P = 0.012) and age ≥11 years
(OR 14.9, P < 0.0001)
Caucasian (304) Not stated; 3
centers
7 genes, 41 SNPs 8 SNPs in 4 genes
with P < 0.20
1 (different) SNP in CELF-2
(OR 3.22, P = 0.014). No TIA-1
SNPs or (TG)≥12T≤5 alleles
ARDS (n = 32). Also age ≥11 years (OR 9.20,
P < 0.0001) and asthma (OR 0.20, P = 0.04)
ARDS acute respiratory distress syndrome (including PaO2/FIO2 ≤ 300), CELF-2 elav-like family member 2, CFTR cystic fibrosis transmembrane conductance regulator, IL1-ra interleukin 1 receptor antagonist, MV invasive
(endotracheal tube or tracheostomy) or noninvasive (nasal prongs or face mask)—oxygen delivered by low or high flow via nasal cannula was not considered MV [4], MYLK myosin light chain kinase, OR odds ratio, SNP single
nucleotide polymorphism, SP-B surfactant protein B, TIA-1 T-cell intracellular antigen 1
Quality control: 5–10% genotyped a second time; blinded analysis of genotype to clinical status (but also state; two individuals independently assessed the results from the analyses and assigned genotypes [4]).











Table 2 Some surprising statements about P values, results of Bayesian methods, and empirical evidence supporting the predictions
of Bayesian methods
Surprising P-value misinterpretations (false statements) Correction Reference
The P value is the probability that the null hypothesis is true The P value assumes the null hypothesis is true [10]
P ≤ 0.05 means the null hypothesis is false, or should be rejected P ≤ 0.05 simply flags the data as being unusual if
all the assumptions used to compute it were correct
[10]
P > 0.05 means the null hypothesis is true, or should be accepted P > 0.05 only suggests that the data are not unusual
if all the assumptions used to compute it were correct;
the same data would also not be unusual under
many other hypotheses
[10]
If you reject the null hypothesis because P ≤ 0.05, the chance
your “significant finding” is a false positive is 5%
The P value only refers to how often you would be
in error over very many uses of the test across different
studies, and not in a single use of the test
[10]
Surprising results of Bayesian methods
In late-phase clinical trials with equipoise (the prior probability of the null hypothesis is 50%), a study with a P = 0.05 makes the posterior
probability of the null hypothesis no less than 13%
[11]
In more exploratory research (the prior probability of the null hypothesis is, say, 75%), a study with a P = 0.05 or P = 0.01 makes the
posterior probability of the null hypothesis no less than 31% and 10%, respectively
[11]
An adequately powered (80%) exploratory epidemiologic (prior 1:10, bias 0.3, α = 0.05) study with a statistically significant finding has a
positive predictive value (PPV) 20% and, if underpowered (20%), a PPV of 10%
[12]
In large traditional cohort studies (prior 1:20, bias 0.1, α = 0.05, power 90%), the false positive to false negative ratio of findings is 32:1 [13]
In a well done (power 95%, α = 0.05) cohort study testing SNPs with less than compelling evidence (prior 1:100), with a statistically significant
finding (P = 0.05 or 0.01) the PPV is 16.1% and <60%; even with fairly compelling prior evidence (prior 1:10), the PPV is 67.9% and <90%
[14]
Surprising empirical evidence supporting the predictions of Bayesian methods
In traditional genome epidemiology [a “few candidate risk factors are selected based on diverse considerations” (low prior); small sample
size (low power, given the small size of expected effect); “discovery hunting using conventional levels” of statistical significance,
confounding, selective reporting (bias)], the crude replication rate of statistically significant genetic associations is ~1.2%
[13]
Hallmarks of discovery exploratory research (low priors, low BF, high bias): “vibration of effects” (evidence of inflated early effect sizes in
epidemiologic associations), “Proteus phenomenon” (a rapid early sequence of extreme, opposite results in retrospective hypothesis-
generating molecular research), and “winners curse” (the first positive study provides inflated estimates compared to reality)
[12, 13]
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PPV is lowered by low study power (smaller studies
with small expected effect sizes), low pre-study odds
(hypothesis-generating experiments), bias (flexibility in
designs, definitions, outcomes, and analytic modes),
and number of teams working in the field (hotter sci-
entific fields) [12]. There are some surprising results
of Bayesian methods (Table 2).
Empirical considerations: when is a gene-association
hypothesis supported?
There is evidence to support the predictions from
Bayesian methods in interpreting study results (Table 2).
This is particularly so in genetic-association studies
where the expected true (when there is a true associ-
ation) odds ratios for common SNPs with common
complex diseases (such as ARDS) is repeatedly found to
be 1.1–1.4; this means that studies have low power un-
less there are >1000 subjects [12, 15]. This empirical
evidence (Table 2) suggests that Bayesian methods,
which keep statistical evidence (conveyed traditionally
by the P value and more usefully by the BF) distinct
from inductive inferences about hypotheses, are usefulbecause they incorporate data external to the study
(estimation of priors) in order to arrive at a conclu-
sion about a hypothesis (posterior probability of the
probed association being true) [9–12].
Interpreting ARDS gene-association studies
Using the growing cohort of patients, six ARDS gene-
association studies have been published by this group
(Table 1) [2–7]. These reports were well done according
to reporting guidelines [15]. We ask three questions to
improve interpretation of these (and, in general, future)
gene-association studies in critical care.
1. Priors: how likely is an association to be expected
given information external to the study?
Considerations are listed in Table 3. In gene-
association studies for complex diseases, the prior is
usually in the range of 0.001 (SNPs with only limited
prior evidence) to 0.1 (SNPs that already show fairly
compelling evidence for association), and in non-
replication studies is likely closer to 0.001 [14].
2. Minimum BF and PPV: what does the evidence from
the study show us? Considerations are listed in
Table 3 Considerations relevant to interpretation of the results of gene-association studies for the risk of ARDS
Question Considerations References
What is the prior probability of the
gene association?
Pathophysiology of ARDS is very complex [1]
Severity of ARDS likely also depends on the inciting cause (e.g., pathogen)
and its duration prior to appropriate treatment
[15]
Many gene-association studies are the first to examine for an association between
the particular genes with the development of ARDS in a hot field of interest
[12, 13]
It may be unknown if the SNPs are associated with changes in their respective
protein levels or function (e.g., there is no change in the amino acid sequence
of the CELF-2 protein)
[2]
The rationale for exploration for a gene association is often based on limited prior
information (e.g., the current study was done because of the previous finding, in
one study with the same cohort, that CFTR gene variants are associated with ARDS
in African American children with CAP)
[3, 13, 14]
What is the minimum BF observed,
or the PPV?
The minimum BF for a P = 0.03 and P = 0.01 are 0.095 and 0.036, respectively. This
modifies the prior: even if very high (e.g., prior of 0.25 for the alternative hypothesis),
the null hypothesis probability is lowered to no less than 22% or 10%, respectively
[11]
The PPV, assuming a prior of 0.01, power 0.80, and P values between 0.001 to 0.01,
is between 55–90%; assuming a more realistic prior of 0.001, the PPV is 10–50%
[14]
Given the expected odds ratios of gene association for complex diseases such as
ARDS are <1.5, and the often low number of patients with ARDS, the power of
the study was well below 0.5. This lowers the PPV even more
[12, 15]
How much bias occurred? Attrition bias: not all the cohort has genotyping done. In this example:
-The number of patients is often lower in more recent times
[15]
Selection bias: flexibility in eligibility criteria due to different definitions of conditions.
In this example:
-CAP definition required at least two of tachypnea, dyspnea, or hypoxemia, but in
one study the list also included cough or abnormal chest exam (selection bias)
[6, 12, 13, 15]
Analysis and reporting biases: flexibility in definitions of predictor variables, in
decisions of which covariates to adjust for, in decisions of outcomes to examine,
and in which analyses to report. In this example:
[12, 13, 15]
a. Predictor variables definitions: only in the CFTR studies was age categorized
as <11 versus ≥11 years; the cohorts were analyzed separately, although in other
studies African Americans and Caucasians were combined or only results for
African Americans were reported
[2, 3, 4, 6, 7]
b. Covariates to adjust for: in the one study where it was examined, a statistically
significant association was “lost” if adjusted for bacterial culture positivity; asthma
was forced into the multiple regressions in only this most recent study; other
known SNPs were not adjusted for (especially those the same group previously
found associated with ARDS: IL-1ra A1 allele, SP-B); duration of symptoms prior
to enrolment, treatment (e.g., antibiotics), and duration of treatment are not
reported or adjusted for
[2, 4, 6]
c. Outcomes to determine and report: the outcome was ARDS, but in other
studies also included mechanical ventilation, severe sepsis, vasopressor use,
and renal or hematologic dysfunction, and could include hospital admission,
PICU admission, and duration of hospitalization
[3, 4–7]
ARDS acute respiratory distress syndrome, BF Bayes factor, CAP community acquired pneumonia, CELF-2 elav-like family member 2, CFTR cystic fibrosis transmembrane
conductance regulator, IL1-ra interleukin 1 receptor antagonist, PPV positive predictive value, SNP single nucleotide polymorphism, SP-B surfactant protein B
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for a prior of 0.01 the PPV is (assuming power of
0.5) 38–82%, and for a prior of 0.001, 8–40% [14].
3. Bias: do we need to modify these estimates for study
bias? Considerations are listed in Table 3. If bias is
low (0.05–0.2 = “the proportion of probed analyses
that would not have been ‘research findings’, but
nevertheless end up presented and reported as such,
because of bias”), power is 50%, and prior is veryhigh (0.1), the PPV that a statistically significant
finding is true is 35–55% [12].
Conclusions
The observed evidence (the P value, or better yet, the BF)
can be combined with prior considerations of plausibility
to determine how well two hypotheses are supported
(posterior probability, PPV). The posterior probability
(PPV) that there is an association between exploratory
Rimpau and Joffe Critical Care  (2016) 20:402 Page 5 of 5SNPs and severity of ARDS in children is low given the
low prior probability, the modest BF (reflected in modest
P values and power), and potential for bias. This is not
necessarily a problem if our interest is in generating hy-
potheses for further scientific study [13]. An interesting
hypothesis has been suggested (i.e., a gene association)
and warrants further investigation; we should wait for rep-
lication in additional larger studies before accepting this
hypothesis. These future studies will have a prior probabil-
ity that is closer to 0.1 (the posterior probability after the
current study), and thus replication would move us much
further toward accepting the hypothesis [13–15]. Overall,
caution is warranted: most genetic associations for ARDS
in adults have not replicated [8].
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